Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Urinary Bladder Neoplasms 3Neoplasms 3Neoplasm Metastasis 2Urethral Neoplasms 1Ureteral Neoplasms 1Stomach Neoplasms 1Recurrence 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Melanoma 1Lymphoma 1Lung Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma in Situ 1Breast Neoplasms 1

Interventions

pembrolizumab 35Nivolumab 14Docetaxel 11atezolizumab 10Paclitaxel 9Carboplatin 7Gemcitabine 6Cisplatin 6Trastuzumab 5Magnetic Resonance Spectroscopy 5Ipilimumab 5Fluorodeoxyglucose F18 5Cyclophosphamide 5Bevacizumab 5fludarabine 4avelumab 4Specimen Handling 4Psychiatric Rehabilitation 4Oxaliplatin 4Leucovorin 4Fluorouracil 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4cemiplimab 3Taxes 3Polymerase Chain Reaction 3Pemetrexed 3Irinotecan 3Gene Expression Profiling 3Early Intervention, Educational 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × ALT-801 × Genitourinary × Clear all
NCT00496860 2013-07-22

Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies

Altor BioScience

Phase 1 Completed
26 enrolled 13 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡